SouthViews No. 298, 6 October 2025
A Revolution in HIV/AIDS Treatment
By German Velasquez
On September 25, 2025, two voluntary licensing agreements were announced between Gilead, the patent holder, and generic drug manufacturers in India for the supply of generic lenacapavir at $40 (instead of the original $28,218) per patient per year. However, too many countries are excluded from the agreements.